Results 11 to 20 of about 254,619 (233)

The FDA “Black Box” Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits? [PDF]

Frontiers in Psychiatry, 2019
The decision made in the year 2004 by the U.S. Food and Drug Administration (FDA) to require a boxed warning on antidepressants regarding the risk of suicidality in young adults still represents a matter of controversy.
Michele Fornaro, Michele Fornaro, Annalisa Anastasia, Annalisa Anastasia, Alessandro Valchera, Alessandro Valchera, Alessandro Carano, Alessandro Carano, Laura Orsolini, Federica Vellante, Gabriella Rapini, Luigi Olivieri, Serena Di Natale, Giampaolo Perna, Giovanni Martinotti, Massimo Di Giannantonio, Domenico De Berardis, Domenico De Berardis, Domenico De Berardis   +18 more
doaj   +3 more sources

Antidepressants and age [PDF]

SSRN Electronic Journal, 2011
Antidepressants as a commodity have been remarkably little-studied by economists. This study shows in new data for 27 European countries that 8% of people (and 10% of those middle-aged) take antidepressants each year.
Blanchflower, David G., Oswald, Andrew J.   +1 more
core   +5 more sources

Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression?

Frontiers in Pharmacology, 2022
Dopamine and its receptors are currently recognized targets for the treatment of several neuropsychiatric disorders, including Parkinson’s disease, schizophrenia, some drug use addictions, as well as depression.
Fangyi Zhao, Fangyi Zhao, Ziqian Cheng, Ziqian Cheng, Jingjing Piao, Jingjing Piao, Ranji Cui, Ranji Cui, Bingjin Li, Bingjin Li   +9 more
doaj   +1 more source

The Genetic Underpinnings of Affective Temperaments: Identifying Novel Risk Variants with a Whole Genome Analytical Approach

European Psychiatry, 2022
One reason behind the failure to understand the neurobiological background of affective disorders and develop more effective treatments is their heterogeneity warranting identification of clinically meaningful endophenotypes.
X. Gonda, N. Eszlari, D. Torok, Z. Gal, A. Millinghoffer, P. Antal, G. Juhasz, G. Bagdy   +7 more
doaj   +1 more source

Association of genetic variants of Glutamate Metabotropic Receptor 5 gene and state-anhedonia

European Psychiatry, 2022
Introduction Andedonia is one of the core symptoms of depression. It is known that in case of depressed individuals experiencing anhedonia, the classical antidepressants are often ineffective, thus investigation of this symptom would be essential ...
D. Török, X. Gonda, Z. Gal, N. Eszlari, G. Bagdy, G. Juhasz, P. Petschner   +6 more
doaj   +1 more source

Epigenetic Mechanism of Early Life Stress-Induced Depression: Focus on the Neurotransmitter Systems

Frontiers in Cell and Developmental Biology, 2022
Depression has an alarmingly high prevalence worldwide. A growing body of evidence indicates that environmental factors significantly affect the neural development and function of the central nervous system and then induce psychiatric disorders.
Ziqian Cheng, Ziqian Cheng, Jingyun Su, Jingyun Su, Kai Zhang, Huiyi Jiang, Bingjin Li, Bingjin Li   +7 more
doaj   +1 more source

Genetic underpinnings of affective temperaments: a pilot GWAS investigation identifies a new genome-wide significant SNP for anxious temperament in ADGRB3 gene

Translational Psychiatry, 2021
Although recently a large-sample GWASs identified significant loci in the background of depression, the heterogeneity of the depressive phenotype and the lack of accurate phenotyping hinders applicability of findings.
Xenia Gonda, Nora Eszlari, Dora Torok, Zsofia Gal, Janos Bokor, Andras Millinghoffer, Daniel Baksa, Peter Petschner, Peter Antal, Gerome Breen, Gabriella Juhasz, Gyorgy Bagdy   +11 more
doaj   +1 more source

Pharmacogenetics of Antidepressants [PDF]

Frontiers in Pharmacology, 2011
Up to 60% of depressed patients do not respond completely to antidepressants (ADs) and up to 30% do not respond at all. Genetic factors contribute for about 50% of the AD response. During the recent years the possible influence of a set of candidate genes as genetic predictors of AD response efficacy was investigated by us and others.
Crisafulli C, Fabbri C, Porcelli S, DRAGO, ANTONIO, Spina E, DE RONCHI, DIANA, SERRETTI, ALESSANDRO   +6 more
openaire   +7 more sources

Neurochemical Changes in the Mouse Hippocampus Underlying the Antidepressant Effect of Genetic Deletion of P2X7 Receptors. [PDF]

, 2013
Recent investigations have revealed that the genetic deletion of P2X7 receptors (P2rx7) results in an antidepressant phenotype in mice. However, the link between the deficiency of P2rx7 and changes in behavior has not yet been explored.
A McQuillin, A Scimemi, AA Boucher, AD Michel, AJ Law, AM Basso, AN Guerra, AV Gourine, B Sperlagh, B Sperlagh, B Sperlagh, Beáta Sperlágh, BP Guiard, C Csolle, C Delarasse, C Lavebratt, C Toro, C Verderio, Cecilia Csölle, CG Thomas, CM Anderson, DS Hasin, DT Balu, E Castren, E Fuchs, E Mundo, E Shimizu, E. Sylvester Vizi, Edit Papp, EJ Nestler, EK Green, F Frenois, F Karege, Flóra Gölöncsér, G Nagy, G Nowak, G Sanacora, G Sanacora, G Sanacora, Gabriella Zsilla, GE Hardingham, GE Wood, JE Malberg, JF Cryan, JF Cryan, JH Meador-Woodruff, JL Warner-Schmidt, JM Boyce-Rustay, JM Krueger, JO Groves, JS Barnholtz, K Hashimoto, K Hejjas, K Martinowich, K Viwatpinyo, K Wager-Smith, KR Tovar, L Backlund, L Bocchio-Chiavetto, L Papp, L Papp, L Patti, L Santarelli, L Stokes, L Zhang, LM Monteggia, M Baranyi, M Barbera-Cremades, M Diaz-Hernandez, M Grigoroiu-Serbanescu, M Koehl, M Masin, M Solle, ME Kozisek, ME Kozisek, ME Szapacs, ML Barbaccia, MT Miras-Portugal, MW Pfaffl, Mária Baranyi, N Barden, N Drigues, O Berton, OH Lowry, P Fossati, P Skolnick, P Soronen, P Vanhoutte, PA Lapchak, Peter Illes, R Dantzer, RC Hogg, RJ Griffiths, RJ Rodrigues, RS Duman, S Alloisio, S Duan, S Lucae, S Monleon, S Schnydrig, SN Williams, SP Banerjee, T Balazsa, T Deltheil, T Deltheil, T Zigova, Thierry Amédée, V Shukla, VF Labrousse, VM Brautigam, W Peng, Y Dwivedi, Y Shirayama, Z Hracskó, Ágnes Kittel   +114 more
core   +21 more sources

Treatment of depression in the elderly with repetitive transcranial magnetic stimulation using theta-burst stimulation: Study protocol for a randomized, double-blind, controlled trial

Frontiers in Human Neuroscience, 2022
IntroductionTranscranial magnetic stimulation (TMS) is a consolidated procedure for the treatment of depression, with several meta-analyses demonstrating its efficacy.
Leandro Valiengo, Leandro Valiengo, Leandro Valiengo, Bianca S. Pinto, Kalian A. P. Marinho, Leonardo A. Santos, Luara C. Tort, Rafael G. Benatti, Bruna B. Teixeira, Cristiane S. Miranda, Henriette B. Cardeal, Paulo J. C. Suen, Julia C. Loureiro, Renata A. R. Vaughan, Roberta A. M. P. F. Dini Mattar, Maíra Lessa, Pedro S. Oliveira, Valquíria A. Silva, Wagner Farid Gattaz, André R. Brunoni, André R. Brunoni, Orestes Vicente Forlenza   +21 more
doaj   +1 more source